age-related macular degeneration

Using OCTA in optometric practice
Using OCTA in optometric practiceBy using OCTA technology, we are able to take better care of our patients with retinal disease, make smarter referrals, or be able to hold on to our patients, knowing a referral is not needed.
Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
Ultra-widefield camera captures images from macula, far peripheryA recently released ultra-widefield fundus camera takes images in true color and captures high-resolution imagess rom the macula to the far periphery.
OCTA system offers exquisite views
OCTA system offers exquisite viewsA new high-density OCT angiography system (AngioVueHD, OptoVue) provides exquisite views of the retinal microvasculature without the need for injection of fluorescein dye.
Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Exploring sirolimus as potential alternative therapy for persistent AMDAnti-vascular endothelial growth factor (VEGF) therapy is highly successful, but as Raj Maturi, MD, pointed out, also has some limitations.
IOL selection important in patients with retinal diseaseWhen dealing with patients with retinal disease, macular disease, or a meaningful risk of retinal detachment, certain types of IOLs should be avoided due to potential complications.
ARVO 2017 showcases vision research advancesAdvances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this year’s meeting of the Association for Research in Vision and Ophthalmology.
5-year CATT analysis finds anti-VEGF drugs a long-term AMD therapyAfter 5 years of follow-up in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), the visual acuity gains achieved during the first 2 years of anti-VEGF treatment were not maintained, the choroidal neovascular lesions continued to evolve with evidence of persistent activity in some eyes, and there was increased retinal thinning and geographic atrophy (GA).